A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses

A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses

BackgroundLung adenocarcinoma (LUAD) kills millions of people every year. Recently, FDA and researchers proved the significance of high tumor mutational burden (TMB) in treating solid tumors. But no scholar has constructed a TMB-derived computing framework to select sensitive immunotherapy/chemother...

Full description

Bibliographic Details
Main Authors:	Wenlong Zhang, Chuzhong Wei, Fengyu Huang, Wencheng Huang, Xiaoxin Xu, Xiao Zhu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Oncology
Subjects:	lung adenocarcinoma tumor mutational burden prediction of prognosis immune landscape immunotherapy chemotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1104137/full

Similar Items

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
by: Congkuan Song, et al.
Published: (2021-01-01)

Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma
by: Ying Li, et al.
Published: (2020-01-01)

High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
by: Dedong Cao, et al.
Published: (2019-09-01)

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
by: Mingming Jia, et al.
Published: (2020-02-01)

Development and validation of an interpretable radiomic signature for preoperative estimation of tumor mutational burden in lung adenocarcinoma
by: Yuwei Zhang, et al.
Published: (2024-04-01)

USH2A Mutation is Associated With Tumor Mutation Burden and Antitumor Immunity in Patients With Colon Adenocarcinoma
by: Yuanyuan Sun, et al.
Published: (2021-11-01)

Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy
by: Ming Chen, et al.
Published: (2018-03-01)

BLM mutation is associated with increased tumor mutation burden and improved survival after immunotherapy across multiple cancers
by: Huiping Shi, et al.
Published: (2024-01-01)

Tumor mutational burden is not predictive of cytotoxic chemotherapy response
by: Mina Nikanjam, et al.
Published: (2020-01-01)

Prognostic necroptosis-related gene signature aids immunotherapy in lung adenocarcinoma
by: Yuqi Song, et al.
Published: (2022-11-01)

Review of Immunogenomics and the Role of Tumor Mutational Burden as a Biomarker for Immunotherapy Response
by: Javier Ros, et al.
Published: (2019-10-01)

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
by: Luochengling Xiang, et al.
Published: (2020-09-01)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
by: Peipei Wang, et al.
Published: (2021-04-01)

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
by: Kai Ma, et al.
Published: (2022-11-01)

Small bowel adenocarcinomas with favorable prognoses by radical resection and adjuvant chemotherapy: a case series of five cases
by: Yuri Nishioka, et al.
Published: (2023-10-01)

Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
by: Ying-Peng Peng, et al.
Published: (2021-11-01)

Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients
by: Qianhe Ren, et al.
Published: (2023-09-01)

Cuproptosis-related signature predicts prognosis, immunotherapy efficacy, and chemotherapy sensitivity in lung adenocarcinoma
by: Gujie Wu, et al.
Published: (2023-03-01)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
by: Lingzhi Hong, et al.
Published: (2022-07-01)

Immunotherapy Combined with Chemotherapy in Relapse Metaplastic Breast Cancer
by: Chen L, et al.
Published: (2023-10-01)

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
by: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, et al.
Published: (2021-11-01)

Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures
by: Chen Huo, et al.
Published: (2021-07-01)

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
by: Ioannis A. Voutsadakis
Published: (2022-02-01)

Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy
by: Xiaodong Yang, et al.
Published: (2021-06-01)

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
by: Lin Li, et al.
Published: (2023-03-01)

Correlate tumor mutation burden with immune signatures in human cancers
by: Xiaosheng Wang, et al.
Published: (2019-01-01)

Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
by: Fereshteh Izadi, et al.
Published: (2021-07-01)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
by: Xiao-Peng Duan, et al.
Published: (2023-01-01)

DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma
by: Didi Yuan, et al.
Published: (2021-09-01)

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations
by: Jianlei Wang, et al.
Published: (2022-11-01)

Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy
by: Xiushen Li, et al.
Published: (2021-11-01)

Association of a Novel Prognosis Model with Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Thyroid Carcinoma
by: Siqin Zhang, et al.
Published: (2021-12-01)

Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers
by: Xian Chen, et al.
Published: (2022-12-01)

Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning
by: Yi Niu, et al.
Published: (2022-06-01)

The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor
by: Saber Amin, et al.
Published: (2020-09-01)

Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma
by: Jun Cheng, et al.
Published: (2022-06-01)

Tumor mutation burden: from comprehensive mutational screening to the clinic
by: Francesca Galuppini, et al.
Published: (2019-08-01)

PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy
by: Xiangmei Li, et al.
Published: (2023-12-01)

The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis
by: Jinlong Cao, et al.
Published: (2022-06-01)

SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer
by: Siyuan Weng, et al.
Published: (2022-07-01)